Garuda - Garba Rujukan Digital

Article Per Year (5 Year)

All

Indonesian Journal of Cancer

ijoc
Website

Published by National Cancer Center-Dharmais Cancer Hospital

ISSN : 19783744 EISSN : 23556811 DOI : https://www.doi.org/ 10.33371

Core Subject : Health, Science,

Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Public Health

Indonesian Journal of Cancer is a peer-reviewed and open-access journal. This journal is published quarterly (in March, June, September, and December) by Dharmais Cancer Hospital - National Cancer Center. Submissions are reviewed under a broad scope of topics relevant to experimental and clinical cancer research. Articles are original research that needs to be disseminated and written in English. All submitted manuscripts will go through the double-blind peer review and editorial review before being granted acceptance for publication. The journal publishes original research articles, case reports, and review articles under the following categories: cancer management, cancer prevention, cancer etiology, epidemiology, molecular oncology, cancer diagnosis and therapy, tumor pathology, surgical oncology, medical oncology, radiation oncology, interventional radiology, as well as early detection.

Arjuna Subject : Kedokteran - Onkologi

Articles 562 Documents

32 33 34 35 36

Survival Analysis in Pediatric Osteosarcoma Mururul Aisyi; Ayu Hutami Syarif; Nur Asih Anggraeni; Adhitya Bayu Perdana; Hutomo Rezky; Agus Kosasih; Achmad Basuki
Indonesian Journal of Cancer Vol 13, No 2 (2019): June
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: Osteosarcoma is the most common bone malignancy in childhood and adolescence. Despite significant advances in diagnostic and therapeutic modalities, osteosarcoma has generally poor prognosis. Several studies highlighted the prognostic significance of demographic and clinical parameters in the pediatric population. Controversy exists about which obvious factors of mortality in some institutions. Meanwhile, little is known about the overall survival (OS) of pediatric osteosarcoma in Dharmais Cancer Hospital.The aim of this study is to estimate the OS in pediatric osteosarcoma.Methods: This retrospective cohort study enrolled 41 children with osteosarcoma during the period of January 2010-September 2017. Patients were selected using inclusion and exclusion criteria. Overall survival (OS) and patient variables were plotted using Kaplan-Meier.Results: Our result showed that all patients admitted to our hospital in advanced stages (IIB and III). Their median OS was 23 months (12.3-33.7 months) with the survival probability was 29.4%.Conclusions: Median OS of pediatric osteosarcoma in our institution was 23 months and the survival probability was 29.4%. It can be used as evidence showing lack of cancer awareness and early detection in our country.

Early Experience of Oncological Reconstructive Surgery at Dharmais National Cancer Center Rian Fabian Sofyan; Bayu Brahma; Iskandar Iskandar; Putri Naura
Indonesian Journal of Cancer Vol 15, No 4 (2021): December
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: Oncological reconstructive surgery is a new paradigm in which it combines oncologic principles with reconstruction techniques. This study aims to present patients’ characteristics who had undergone oncological reconstructive surgery at the Department of Surgical Oncology, Dharmais National Cancer Center. Methods: This descriptive study identified patients’ characteristics who underwent oncological reconstructive surgery, their cancer types, and their therapies. All data were obtained from surgery registration and medical records from January 2019 to January 2020. Data were then presented in number and percentage.Results: A total of 174 patients had undergone oncological reconstructive surgery within one year. The mean age of all patients was 48.2 ± 16.7 years old. Most patients were female (72.1%), with breast cancer making up most cases (43.7%). Most of the participants also underwent mastectomy (42.1%), which was later followed by various reconstruction types. Sixty patients received free tissue transfer with microsurgery (34.4%), of which head and neck cancer constituted most cases. In addition, the most common donor site for the free flap was the Anterolateral Thigh (41.7%). Of all 174 patients, 75.2% presented with locally advanced cancer, and 17.8% had metastatic cancer. Within one year of follow-up, the survival rate was 87.4%, while local recurrence was 3%. Conclusions: The oncological reconstructive surgery approach plays a therapeutic and reconstructive role, and such might be the preferred method of choice for patients presenting with advanced-stage cancer

Radical Cystectomy Procedures in Fatmawati General Hospital, Jakarta, Indonesia: Preliminary Report Syamsu Hudaya; Karina Evelyn Sidabutar
Indonesian Journal of Cancer Vol 13, No 1 (2019): March
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: Radical cystectomy (RC) and urinary diversion (UD) are among the most complex urological procedures with high postoperative morbidity, That caused only a few urologists are prepared to perform this operation. We dedicated to enroll this procedure since the number of bladder tumor cases is increasing in our third referral general hospital. We evaluate and analyze variables related to the surgical and direct post-operative outcomes of our initial experience of radical cystectomy.Methods: This retrospective descriptive study collected medical record of patients with RC in Fatmawati Hospital, Jakarta, Indonesia from 2014-2016. All surgeries were performed by the same surgeon. Variables related to the surgical and postoperative outcomes and complications in the patients were analyzed.Results: There were 11 patients during this study period. The average age of the patients was 60.9 ± 9.6 years old with 7 male and 4 female patients. All patients underwent ileal conduit as urinary diversion. The mean operation time was 392.7 ± 117 minutes. The estimated blood loss was 1,272.7 ± 538.7 mL. No intraoperative death was recorded. The hospital stay length was 15.8 ± 8.3 days, visual analog scale (VAS) score in the first day after surgery was 2.7 ± 0.2, and the drain was kept in for 13.9 ± 7.4 days. All of the histopathology results were urothelial carcinomas.Conclusions: Our initial experience with radical cystectomy results in acceptable blood loss, manageable post-operative pain, and acceptable hospital stay. Therefore it is still a treatment of choice for muscle-invasive bladder cancer in our hospital.

Terapi Radikal pada Penderita Kanker Prostat: Tindak Lanjut Jangka Panjang dan Faktor Prediksi Survival RAINY UMBAS; CHAIDIR A MOCHTAR; RIZAL A HAMID
Indonesian Journal of Cancer Vol 4, No 2 (2010): Apr - Jun 2010
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v4i2.87

Radical treatment in the form of radical prostatectomy (PR) or external beam radiotherapy (EBRT) considered as gold standard in the management of localized and in some selected cases of locally advanced prostate cancer patients. Aim of this study is to know the treatment results of RP and EBRT in prostate cancer patients with T1-3 at Cipto Mangunkusumo Hospital and Dharmais Cancer Hospital, Jakarta. Analysis to the prediction factors in those two treatment modalities was also done. There were 110 patients among 610 prostate cancer patients in those two hospitals between January 1995 and December 2007 who received radical treatment. Radical prostatectomy was done to 43 patients with median age of 63 years (range: 50-74 years), and the other 67 patients with median age of 70 years (range: 50-82 years) were treated by EBRT. Median survival was 101 months and 85 months for patients treated with RP and EBRT respectively while 5-year survival rate was 68.4% and 69.2% for those respective groups. There was no clinical parameter in the group of patients who underwent PR which significantly correlated with survival. In the EBRT group, low grade tumor was significantly correlated with better survival. In conclussion, less than 20% of prostate cancer patients in those two hospitals underwent radical treatment in form of PR or EBRT. Median survival for patients treated with PR was better than those who received EBRT. Tumor grade was the only survival predictor factor in the EBRT group.

Faktor Klinis dan Histopatologi serta Hubungannya dengan Kekambuhan Pascaoperasi pada Pasien Kanker Payudara di RSUD Dr. Soetomo, Januari–Juni 2015 KEZIA EVELINE; HERU PURWANTO; PUDJI LESTARI
Indonesian Journal of Cancer Vol 11, No 2 (2017): April - June
Publisher : National Cancer Center - Dharmais Cancer Hospital

ABSTRACT Breast cancer recurrence occurs because of factors such as surgical problem and clinicopathological features. The present study aimed to assess the relation between clinicopathological factors to breast cancer recurrence. Cross sectional design was used to take medical documents of all patients who visited Out Patient Department Soetomo Hospital from January 2015 to June 2015. A total of 228 patients were identified. The rates of breast cancer recurrence were 30%, most of recurrence occurred in first 5 years and the peak was in the first year. There were significant correlations between breast cancer recurrence and the factors observed below: tumor size [p=0.01,PR(95% CI)=1.621(1.086-2.421)]; nodal status 1-3 and ≥ 4 ≥ 4 [respectively p=0.014,PR(95%CI)=1.281(1.030-2.593) ; p=0.011,PR(95%CI) =1.289(1.038-1.601)]; tumor location [p=0.00,PR(95%CI)=2.422(1.576-3.721)]; hospital where the operation performed [p=0.03,PR(95%CI)=1.207(1.026-1.421)]; adjuvant therapy [p=0.00,PR(95%CI)= 4.371(2.231- 8.566)]. However there were no correlations of breast cancer recurrence and age, clinical stage or type of surgery. Conclusion, there are significant correlations between breast cancer recurrence and clinicopathological factors, such as tumor size, nodal status, tumor location, hospital where the operation performed and adjuvant therapy ABSTRAKKekambuhan kanker payudara terjadi karena beberapa faktor, di antaranya faktor klinis dan histopatologis. Penelitian ini bertujuan untuk mengetahui hubungan faktor klinis dan histopatologi terhadap kekambuhan. Penelitian ini menggunakan desain cross sectional dengan mengambil data dari rekam medis pasien yang berkunjung ke Unit Rawat Jalan RSUD Dr. Soetomo periode Januari- Agustus 2015. Sebanyak 228 pasien diidentifikasi. Tingkat kekambuhan kanker payudarasebsar 30%, sebagian besar kekambuhan terjadi dalam 5 tahun pertama, dan puncaknya adalah pada tahun pertama. Ada hubungan yang signifikan antara kekambuhan kanker payudara dengan faktor-faktor yang diamati: ukuran tumor [p=0,01, PR (95%CI) =1,621 (1.086-2.421)]; status nodal 1-3 and ≥ 4 ≥ 4 [masing-masing p=0,014,,PR(95%CI) = 1.281(1.030-2.593); p=0,011, PR (95%CI) = 1.289(1.038-1.601)]; letak tumor [p=0,00, PR(95%CI) = 2.422(1.576-3.721)]; rumah sakit tempat operasi dilaksanakan[p=0,03, PR,(95%CI)=1.207(1.026-1.421)]; terapi adjuvant [p=0,00, PR(95%CI)= 4.371(2.231-8.566)]. Namun, tidak ada korelasi antara kekambuhan kanker payudara dengan usia, stadium klinis, dan jenis operasi. Kesimpulan, terdapat hubungan yang signifikan antara kekambuhan kanker payudara dengan ukuran tumor, status nodal, lokasi tumor, rumah sakit di mana operasi dilaksanakan, dan terapi adjuvant.

Acute and Late Toxicity In Breast Cancer Patient That Received Hypofractionated Adjuvant Radiotherapy after Breast Conserving Surgery: A Case Report Sinta Prastiana Dewi; Henry Kodrat
Indonesian Journal of Cancer Vol 14, No 4 (2020): December
Publisher : National Cancer Center - Dharmais Cancer Hospital

Introduction: Breast cancer is the most common female malignancy worldwide. Breastconserving surgery followed by adjuvant radiotherapy is a preferable treatment option. Hypofractionated radiotherapy is an attractive fractionation scheme because of its shorter treatment duration. This paper aims to report the short-term and long-term toxicity of hypofractionated radiotherapy in breast cancer patients at our institution. Case Presentation: A 58-year-old woman with right breast cancer T2N1M0 had undergone breast-conserving surgery with axilla lymph node dissection. This patient underwent adjuvant whole breast radiotherapy with a dose of 42.56 Gy in 16 fractions followed by tumor bed boost with a dose of 16 Gy in 8 fractions. After undergoing the fourth fraction of boost, she had hyperpigmentation on her radiation area (RTOG skin toxicity grade 1). At the 6-month follow-up, the hyperpigmentation still appeared. Until the 24-month follow-up, after she completed radiotherapy, there was no sign of tumor recurrence and toxicity.Conclusion: Hypofractionated radiotherapy could be an option for breast cancer treatment that provides equivalent local control, survival, and side effects to conventional fractionation radiotherapy.

Peran Dokter Gigi Anak Menurut Protokol Onkologi pada Pasien Kanker Anak SRI RATNA LAKSMIASTUTI; EDI SETIAWAN TEHUTERU
Indonesian Journal of Cancer Vol 9, No 4 (2015): Okt - Des 2015
Publisher : National Cancer Center - Dharmais Cancer Hospital

ABSTRACTNowadays, cancer is the cause of death in sixth rank in the world. About 2% of total cancer, is predicted occuring thechildren. Health Data 2007, mention that in Indonesia every year was found about 4,100 new children cancer patient.Children cancer patient, generally have to undergo long-term treatment and often make them uncomfortable. Decreaseendurance body which is significant and serious infection that begins in the oral cavity is often occur. This will increasethe risk of death to the patient. In addition, there are also some types of cancer which manifest in the oral cavity. Thedentist may be the first to find this abnormality. To provide information to the dentist, specially pediatric that theyshould have enough knowledge about cancer in children. As well as need to know the steps and dental management inorder to be able to contribute and plays important role in improving oral health children with cancer. Cancer is definedas uncontrolled growth of the cells that invade and cause damage to surrounding tissue. Cancer is a disease with variedjournay and not infrequently leads to death. Treatments that can be perform on children cancer patient consist ofsurgery, radiotherapy, chemotherapy, or combination. A pediatric dentist is highly requested to know about dentalmanagement children cancer patient. Pediatric dentist should take a comprehensive interview to find the history ofdisease, do a proper clinical examination, cooperation with the expert, establishing diagnosis and performingappropriate treatment plan.ABSTRAKDewasa ini, kanker menjadi penyebab kematian populasi manusia di urutan keenam. Diperkirakan, sekitar 2?3% darikeseluruhan kasus kanker menyerang anak. Data kesehatan tahun 2007 menyebutkan bahwa di Indonesia setiap tahunditemukan sekitar 4.100 kasus baru anak dengan kanker. Pasien kanker anak pada umumnya harus menjalani perawatanjangka panjang dan seringkali membuat tidak nyaman penderitanya. Penurunan daya tahan tubuh yang signifikan daninfeksi serius yang berawal di rongga mulut seringkali terjadi. Hal ini akan memperbesar risiko kematian pasien. Selainitu, juga terdapat beberapa jenis kanker yang bermanifestasi di rongga mulut. Dokter gigi dapat menjadi orang pertamayang menemukan kelainan tersebut. Artikel ini disusun untuk memberikan informasi kepada para dokter gigi,khususnya dokter gigi anak, tentang pentingnya memiliki pengetahuan yang cukup mengenai kanker pada anak sertatindakan dan perawatan yang harus dilakukan di bidang kedokteran gigi, agar bisa memberikan kontribusi danberperan penting dalam meningkatkan kesehatan gigi serta mulut pasien kanker anak. Kanker didefinisikan sebagaipertumbuhan sel yang tidak terkontrol yang dapat menyebabkan kerusakan pada jaringan di sekitarnya. Kankermerupakan penyakit dengan perjalanan yang bervariasi dan tidak jarang menuju ke kematian. Perawatan yang dapatdilakukan pada pasien kanker anak terdiri atas bedah, radioterapi, kemoterapi, atau kombinasi. Seorang dokter gigianak harus mengetahui perawatan pasien kanker anak di bidang kedokteran gigi. Dokter gigi anak harus dapatmelakukan anamnesis yang baik untuk menggali informasi tentang riwayat penyakit yang tepat, bekerjasama dengan sejawat ahli, menegakkan diagnosis, dan menentukan rencana perawatan yang tepat

Comparison Study Between Laparoscopic Radical Prostatectomy versus Robotic Radical Prostatectomy in Patient with TUR-P History Moamar Andar Roamare Siregar; Chaidir Arif Mochtar; Rainy Umbas; Agus Rizal Hamid
Indonesian Journal of Cancer Vol 13, No 4 (2019): December
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: The number of men with benign prostate hyperplasia undergoing transurethral resection of prostate (TURP) with the subsequent development of prostate cancer has been increasing. This study aimed to compare the surgical, oncological, and functional outcomes of robotic and laparoscopic radical prostatectomy techniques in patients with the history of TURP.Methods: Literature search of electronic databases was performed through Pubmed, Science Direct, SCOPUS, and CENTRAL databases. Cochrane Risk of Bias Tool was then employed to assess the risk of bias in each study. Grey literature was also searched from sources such as Cancer Care Ontario and conference abstracts. Critical appraisals of included studies were conducted using the Newcastle-Ottawa Scale.Results: The searches located 1258 citations, but only 11 studies were included in the final selection. Most studies had a good methodological quality based on the Ottawa Scale. The mean age of samples was varied among each study from 61.8 to 70.8 years. The TURP history significantly affects biochemical recurrences (OR 2.29, 95% CI 1.14–4.59), intraoperative blood loss (MD 57 ml; 95% CI 6–108 m), prolonged operative duration (MD 20 minutes; 95% CI 3–37 minutes), and surgical complications (OR 2.54, 95% CI 1.79–3.60) following radical prostatectomy for prostate cancer. In the subgroup analysis, only prolonged operative duration and surgical complications were significant both in laparoscopic and robotic radical prostatectomy. There was no association between the TURP history and the positive surgical margin rate in total and subgroup analyses. Conclusions: The previous TURP history affects the outcomes of patients who underwent radical prostatectomy, either laparoscopic or robotic.

Magnetic Resonance Findings in Adolescent Vaginal Rhabdomyosarcoma: A Rare Case Report Trifonia Pingkan; Fitri Juniarta; Hartono Tjahjadi; Meliyana Lai
Indonesian Journal of Cancer Vol 16, No 1 (2022): March
Publisher : National Cancer Center - Dharmais Cancer Hospital

Introduction: Rhabdomyosarcoma (RMS) is a rare soft tissue tumor, mainly affecting children, adolescents, and adults younger than 15 years, representing 3% to 4% of all childhood malignancies. Genitourinary is the second-most-common location of RMS with around 25% of cases. We describe a rare case of vaginal rhabdomyosarcoma in adolescents with huge polypoid tumors. Case Presentation: A 15-year-old female presented with vaginal bleeding for seven months. Her medical story was unremarkable. The clinical examination showed a polypoid mass prolapsed from the vagina, and the laboratory result was anemia. The pelvic magnetic resonance imaging (MRI) showed a heterogenous bulky solid tumor in the vagina. The histopathological finding revealed a sarcoma, and the immunohistochemical staining result was rhabdomyosarcoma not otherwise specified (NOS). Conclusions: Vaginal RMS is a rare malignant tumor of mesenchymal origin with skeletal muscle differentiation. Vaginal RMS is the most common site of genitourinary RMS and presents as a rapidly growing and aggressive local mass. Imaging plays an important role in the initial diagnosis of vaginal RMS, regarding the presentation of the bulky protruding tumor on the vaginal region

Analisis Drug Related Problems pada Pasien Kanker Padat Stadium Lanjut yang Menjalani Terapi Paliatif di Rumah Sakit Kanker Dharmais EMA NILLAFITA PUTRI KUSUMA
Indonesian Journal of Cancer Vol 9, No 2 (2015): April-Juni 2015
Publisher : National Cancer Center - Dharmais Cancer Hospital

ABSTRACTThe goal of palliative care is to increase the quality of life and to reduce the symptomp, but it often increases the complexity of patients therapy. The aim of this study is to evaluate prevalance, the risk factor, and the profile of Drug Related Problems (DRPs) from the palliative therapy patient who suffer from solid cancer at Dharmais Hospital National Cancer Center. This is a cross sectional study and the data was taken from the patients medical records starting from March to June 2011. The patient characteristics who followed this study were 33 patients women (68.8%), and the frequent cases of solid cancer was breast cancer, i.e about 15 patients (31.3%). Most of the patients (64.6%) were in palliative care. Adverse reactions occurred in 70.1% patienst and 66.2% patients got potential adverse reaction. Only 5.7% drug-drug interactions were detected with moderate significance. About 15.0% drug interactions caused by the use of morphine, and amitriptyline at the same time. The risk of incident adverse reactions were influenced by age, sex,history of curative chemotherapy regimen, comorbidities, and the number of drug use. The increasing risk of drug interaction incident was the influenced by the number of drugs using ( > 5 drugs) and if the patient had a comorbidities. Most of patients in the palliative care would get the DRP but drug interactions did not always occur.ABSTRAKTerapi paliatif bertujuan meningkatkan kualitas hidup dan mengurangi gejala, namun akan menambah kompleksitas terapi. Penelitian ini bertujuan mengevaluasi prevalensi, faktor risiko, dan profil kejadian Drug Related Problems (DRPs) terapi paliatif pasien kanker padat stadium lanjut. Penelitian ini adalah penelitian potong lintang. Dan data diambil dari rekam medis pasien bulan Maret Juni 2011. Karakteristik pasien, 33 orang (68,8%) perempuan, dan kasus kanker padat terbesar adalah kanker payudara sebanyak 15 orang (33,3%). Sebagian besar pasien kanker padat stadium lanjut (64,6%) hanya menjalani satu kali terapi paliatif. Reaksi obat yang tidak diinginkan (ROTD) termanifestasi dialami 70,1% subyek uji dan 66,2% uji berpotensi mengalami ROTD. Interaksi obat dengan signifikansi moderate ditemui pada 5,7% terapi pasien. Sebesar 15,0% interaksi tersebut akibat penggunaan morfin dan amitriptilin bersama. Risiko ROTD meningkat karena usia, jenis kelamin, riwayat pemberian regimen kemoterapi kuratif, penyakit penyerta, dan jumlah obat yang digunakan. Peningkatan risiko kejadian interaksi obat dipengaruhi oleh penggunaan > 5 jenis obat dan adanya penyakit penyerta. Pasien kanker padat stadium lanjut yang menjalani terapi paliatif pada umumnya mengalami ROTD, namun jarang ditemukan interaksi obat.

Page 34 of 57 | Total Record : 562

32 33 34 35 36

Filter by Year

2007 2025

Filter By Issues

All Issue Vol 19, No 3 (2025): September Vol 19, No 2 (2025): June Vol 19, No 1 (2025): March Vol 18, No 4 (2024): December Vol 18, No 3 (2024): September Vol 18, No 2 (2024): June Vol 18, No 1 (2024): March Vol 17, No 4 (2023): December Vol 17, No 3 (2023): September Vol 17, No 2 (2023): June Vol 17, No 1 (2023): March Vol 16, No 4 (2022): December Vol 16, No 3 (2022): September Vol 16, No 2 (2022): June Vol 16, No 1 (2022): March Vol 15, No 4 (2021): December Vol 15, No 3 (2021): September Vol 15, No 2 (2021): June Vol 15, No 1 (2021): March Vol 14, No 4 (2020): December Vol 14, No 3 (2020): September Vol 14, No 2 (2020): June Vol 14, No 1 (2020): March Vol 13, No 4 (2019): December Vol 13, No 3 (2019): September Vol 13, No 2 (2019): June Vol 13, No 1 (2019): March Vol 12, No 4 (2018): October-December Vol 12, No 3 (2018): July-September Vol 12, No 2 (2018): April-June Vol 12, No 1 (2018): Jan - Mar Vol 11, No 4 (2017): October- December 2017 Vol 11, No 3 (2017): July - September 2017 Vol 11, No 2 (2017): April - June Vol 11, No 1 (2017): Jan-Mar Vol 10, No 4 (2016): October - December 2016 Vol 10, No 3 (2016): July - September 2016 Vol 10, No 2 (2016): April - June 2016 Vol 10, No 1 (2016): Jan - Mar 2016 Vol 9, No 4 (2015): Okt - Des 2015 Vol 9, No 3 (2015): Jul - Sept 2015 Vol 9, No 2 (2015): April-Juni 2015 Vol 9, No 1 (2015): Jan - Mar 2015 Vol 8, No 4 (2014): Oct - Dec 2014 Vol 8, No 3 (2014): Jul - Sep 2014 Vol 8, No 2 (2014): April-Juni 2014 Vol 8, No 1 (2014): Jan - Mar 2014 Vol 7, No 4 (2013): Oct - Dec 2013 Vol 7, No 3 (2013): Jul - Sep 2013 Vol 7, No 2 (2013): Apr - Jun 2013 Vol 7, No 1 (2013): Jan - Mar 2013 Vol 6, No 4 (2012): Oct - Dec 2012 Vol 6, No 3 (2012): Jul - Sep 2012 Vol 6, No 2 (2012): Apr - Jun 2012 Vol 6, No 1 (2012): Jan - Mar 2012 Vol 5, No 4 (2011): Oct - Dec 2011 Vol 5, No 3 (2011): Jul - Sep 2011 Vol 5, No 2 (2011): Apr - Jun 2011 Vol 5, No 1 (2011): Jan - Mar 2011 Vol 4, No 4 (2010): Oct - Dec 2010 Vol 4, No 3 (2010): Jul - Sep 2010 Vol 4, No 2 (2010): Apr - Jun 2010 Vol 4, No 1 (2010): Jan - Mar 2010 Vol 3, No 4 (2009): Oct - Dec 2009 Vol 3, No 3 (2009): Jul - Sep 2009 Vol 3, No 2 (2009): Apr - Jun 2009 Vol 3, No 1 (2009): Jan - Mar 2009 Vol 2, No 4 (2008): Oct - Dec 2008 Vol 2, No 3 (2008): Jul - Sep 2008 Vol 2, No 2 (2008): Apr - Jun 2008 Vol 2, No 1 (2008): Jan - Mar 2008 Vol 1, No 4 (2007): Oct - Dec 2007 Vol 1, No 3 (2007): Jul - Sep 2007 Vol 1, No 2 (2007): Apr - Jun 2007 Vol 1, No 1 (2007): Jan - Mar 2007 More Issue

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name
Bayu Brahma

Contact Email
journal.cancer@gmail.com

Phone
+628176389956

Journal Mail Official
admin@indonesianjournalofcancer.or.id

Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location
Kota adm. jakarta barat,

Dki jakarta

INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name Bayu Brahma

Contact Email journal.cancer@gmail.com

Phone +628176389956

Journal Mail Official admin@indonesianjournalofcancer.or.id

Editorial Address National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location Kota adm. jakarta barat, Dki jakarta INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Contact Name
Bayu Brahma

Contact Email
journal.cancer@gmail.com

Phone
+628176389956

Journal Mail Official
admin@indonesianjournalofcancer.or.id

Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location
Kota adm. jakarta barat,

Dki jakarta

INDONESIA